Competitive landscape
Drugs aimed at the same indication, from approved to preclinical.
12 drugs for “Pancreatic Ductal Adenocarcinoma”
Approved 2
- RelacorilantCORCEPT THERAPEUTICS INCMetastatic Pancreatic Ductal Adenocarcinoma · next catalyst 17 Dec 2026
- DaraxonrasibRevolution Medicines, Inc.PDAC - Pancreatic Ductal Adenocarcinoma
Phase 3 6
- AtebimetinibImmuneering CorpPDAC - Pancreatic Ductal Adenocarcinoma
- NIS793NOVARTIS AGMetastatic Pancreatic Ductal Adenocarcinoma
- QuemliclustatArcus Biosciences, Inc.Metastatic Pancreatic Ductal Adenocarcinoma
- RMC-6236Revolution Medicines, Inc.PDAC - Pancreatic Ductal Adenocarcinoma
- Telisotuzumab adizutecanAbbVie Inc.Metastatic Pancreatic Ductal Adenocarcinoma
- ZoldonrasibRevolution Medicines, Inc.PDAC - Pancreatic Ductal Adenocarcinoma
Phase 2/3 4
- NavlimetostatBRISTOL MYERS SQUIBB COPancreatic Ductal Adenocarcinoma
- OT-101Oncotelic Therapeutics, Inc.Pancreatic Ductal Adenocarcinoma
- PonsegromabPFIZER INCMetastatic Pancreatic Ductal Adenocarcinoma
- SBP-101Panbela Therapeutics, Inc.Pancreatic Ductal Adenocarcinoma
Drugs whose recorded indications name this term, by development stage. Indications come from registries and labels, so a drug can appear under related terms.